Nucs AI Company Profile

Background

Nucs AI, founded in 2023 and headquartered in San Francisco, is a healthcare technology company specializing in artificial intelligence (AI) solutions for prostate cancer management. The company's mission is to harness AI to transform the clinical management of prostate cancer, providing healthcare professionals with advanced tools for precise diagnosis and personalized treatment plans. Nucs AI envisions becoming a global leader in AI-driven prostate cancer solutions, setting new standards in cancer care through continuous innovation.

Key Strategic Focus

Nucs AI focuses on integrating AI with medical imaging to enhance diagnostic accuracy and efficiency in prostate cancer care. The company's core objectives include developing AI-powered tools that automate tumor detection, staging, and quantification, thereby improving clinical workflows and patient outcomes. Nucs AI's primary markets are healthcare institutions and research organizations seeking advanced solutions for prostate cancer diagnostics and treatment planning.

Financials and Funding

In December 2024, Nucs AI secured $3.5 million in seed funding. The capital is intended to enhance the company's AI platform, support FDA clearance processes, and expand research and development efforts. The investors in this funding round remain undisclosed.

Pipeline Development

Nucs AI has developed two key products:

• DeepPSMA: An AI-driven tool that enables rapid and reliable detection, staging, and quantification of prostate cancer using PSMA-PET/CT imaging. It calculates TNM stages and generates quantitative tumor burden metrics, facilitating personalized treatment planning.

• SelectPSMA: An AI-powered solution that predicts patient outcomes following treatment with PSMA-targeted radiopharmaceuticals, assisting in identifying patients unlikely to benefit from such treatments and minimizing potential side effects.

Both products are designed to integrate seamlessly into clinical workflows, providing evidence-based insights to healthcare professionals.

Technological Platform and Innovation

Nucs AI's technological platform leverages advanced AI algorithms to analyze PSMA-PET/CT imaging data, offering:

• Proprietary Technologies: DeepPSMA and SelectPSMA, which automate tumor analysis and predict treatment responses, respectively.

• Scientific Methodologies: Utilization of discriminative AI for accurate tumor detection and staging, and predictive analytics for personalized treatment planning.

These innovations aim to reduce manual analysis time, enhance diagnostic accuracy, and improve patient outcomes.

Leadership Team

• Nijat Ahmadov: Co-Founder and CEO. Under his leadership, Nucs AI has achieved significant milestones, including securing seed funding and receiving the Cannes Neuron Award for Healthcare Innovation.

• Farid Yagubbayli: Co-Founder. He has played a pivotal role in developing the company's AI-driven solutions and expanding its market presence.

Leadership Changes

As of May 2025, there have been no significant changes or appointments within Nucs AI's leadership team.

Competitor Profile

Market Insights and Dynamics

The AI-driven radiology market is experiencing rapid growth, driven by the increasing prevalence of prostate cancer and the demand for precision medicine. Prostate cancer cases are projected to double by 2024, highlighting the need for advanced diagnostic and treatment solutions.

Competitor Analysis

Key competitors in the AI-driven radiology space include:

• Arterys: Specializes in AI-powered medical imaging solutions across various modalities.

• Zebra Medical Vision: Offers AI-based tools for radiology, focusing on automated detection of diseases.

• Aidoc: Provides AI solutions for radiologists to flag acute abnormalities in medical imaging.

These companies focus on enhancing diagnostic accuracy and efficiency through AI integration in medical imaging.

Strategic Collaborations and Partnerships

Nucs AI has established clinical partnerships with leading institutions, including Johns Hopkins, to advance its AI-driven radiology solutions. These collaborations aim to validate and refine the company's technologies, ensuring their effectiveness in clinical settings.

Operational Insights

Nucs AI's strategic considerations include:

• Regulatory Expansion: Pursuing FDA clearance for DeepPSMA and SelectPSMA to set new standards in AI-assisted radiology diagnostics.

• Clinical Impact: Scaling adoption in hospitals and research institutions to drive personalized and data-driven medical imaging.

• Innovation Pipeline: Developing next-generation AI tools for automated radiology reporting and treatment response evaluation.

These initiatives position Nucs AI to capture a significant share of the expanding AI radiology market.

Strategic Opportunities and Future Directions

Nucs AI is committed to driving the future of AI-powered radiology by:

• Achieving Regulatory Approvals: Securing FDA clearance to enhance credibility and market reach.

• Expanding Clinical Adoption: Increasing the use of its AI solutions in healthcare institutions globally.

• Advancing AI Capabilities: Continuing research and development to introduce innovative tools that further optimize imaging workflows.

These strategic directions aim to solidify Nucs AI's position as a leader in AI-driven prostate cancer solutions.

Contact Information

• Website: www.nucs.ai

• LinkedIn: Nucs AI LinkedIn Profile

• Twitter: @nucs_ai

• Facebook: Nucs AI Facebook Page

For media inquiries or partnership opportunities, please visit the company's official website.